Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 19 10 2018
revised: 23 01 2019
accepted: 14 04 2019
pubmed: 28 5 2019
medline: 31 12 2019
entrez: 25 5 2019
Statut: ppublish

Résumé

Smartphone apps and wearable devices could augment clinical practice by detecting changes in health status for multiple sclerosis (MS). This study sought to investigate potential barriers and facilitators for uptake and sustained use in (i) people with both relapsing remitting MS (RRMS) and progressive MS (PMS) and (ii) across different countries. Twenty four participants with MS took part in four focus groups held in three countries (2 in the UK, 1 in Spain, and 1 in Italy) to investigate potential barriers and facilitators for mHealth technology. A systematic thematic analysis was used to extract themes and sub-themes. Facilitators and barriers were organised into functional technology-related factors and non-functional health-related and user-related factors. Twelve themes captured all requirements across the three countries for both RRMS and PMS. Key requirements included accommodation for varying physical abilities, providing information and memory aids. Potential negative effects on mood and providing choice and control as part of overcoming practical challenges were identified. We took a cross-national perspective and found many similarities between three European countries across people with RRMS and PMS. Future provision should accommodate the key requirements identified to engage people with MS in scalable mHealth interventions.

Sections du résumé

BACKGROUND BACKGROUND
Smartphone apps and wearable devices could augment clinical practice by detecting changes in health status for multiple sclerosis (MS). This study sought to investigate potential barriers and facilitators for uptake and sustained use in (i) people with both relapsing remitting MS (RRMS) and progressive MS (PMS) and (ii) across different countries.
METHODS METHODS
Twenty four participants with MS took part in four focus groups held in three countries (2 in the UK, 1 in Spain, and 1 in Italy) to investigate potential barriers and facilitators for mHealth technology. A systematic thematic analysis was used to extract themes and sub-themes.
RESULTS RESULTS
Facilitators and barriers were organised into functional technology-related factors and non-functional health-related and user-related factors. Twelve themes captured all requirements across the three countries for both RRMS and PMS. Key requirements included accommodation for varying physical abilities, providing information and memory aids. Potential negative effects on mood and providing choice and control as part of overcoming practical challenges were identified.
CONCLUSIONS CONCLUSIONS
We took a cross-national perspective and found many similarities between three European countries across people with RRMS and PMS. Future provision should accommodate the key requirements identified to engage people with MS in scalable mHealth interventions.

Identifiants

pubmed: 31125754
pii: S2211-0348(19)30180-4
doi: 10.1016/j.msard.2019.04.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-132

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Sara K Simblett (SK)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. Electronic address: sara.simblett@kcl.ac.uk.

Joanne Evans (J)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Ben Greer (B)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Hannah Curtis (H)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Faith Matcham (F)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Marta Radaelli (M)

Neurology services, San Raffaele Hospital MS centre, Milan, Italy.

Patricia Mulero (P)

Centre d´esclerosi multiple de Catalunya, Hospital Vall d´Hebron, Barcelona, Spain.

Maria Jesús Arévalo (MJ)

Centre d´esclerosi multiple de Catalunya, Hospital Vall d´Hebron, Barcelona, Spain.

Ashley Polhemus (A)

MSD IT Global Innovation Center, Prague, Czech Republic.

Jose Ferrao (J)

MSD IT Global Innovation Center, Prague, Czech Republic.

Peter Gamble (P)

MSD IT Global Innovation Center, Prague, Czech Republic.

Giancarlo Comi (G)

Neurology services, San Raffaele Hospital MS centre, Milan, Italy.

Til Wykes (T)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH